Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cara Therapeutics (CARA)

Cara Therapeutics (CARA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,463
  • Shares Outstanding, K 4,574
  • Annual Sales, $ 20,970 K
  • Annual Income, $ -118,510 K
  • EBIT $ -86 M
  • EBITDA $ -84 M
  • 60-Month Beta 0.50
  • Price/Sales 3.24
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 49.06%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -6.72
  • Growth Rate Est. (year over year) +14,966.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.30 +19.30%
on 03/05/25
5.31 -3.39%
on 02/18/25
-0.07 (-1.35%)
since 02/14/25
3-Month
2.71 +89.41%
on 12/18/24
6.36 -19.34%
on 12/31/24
+1.99 (+63.17%)
since 12/13/24
52-Week
2.71 +89.41%
on 12/18/24
11.52 -55.47%
on 03/28/24
-4.31 (-45.65%)
since 03/14/24

Most Recent Stories

More News
Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split

CARA : 5.13 (+1.38%)
Cara: Q3 Earnings Snapshot

Cara: Q3 Earnings Snapshot

CARA : 5.13 (+1.38%)
Cara: Q2 Earnings Snapshot

Cara: Q2 Earnings Snapshot

CARA : 5.13 (+1.38%)
Cara: Q1 Earnings Snapshot

Cara: Q1 Earnings Snapshot

CARA : 5.13 (+1.38%)
Cara: Q4 Earnings Snapshot

Cara: Q4 Earnings Snapshot

CARA : 5.13 (+1.38%)
Mira Pharmaceuticals Stock Is Soaring In November... Here's Why

Leveraging a favorable DEA classification for its synthetic analog of THC, Mira Pharmaceuticals could be on an expedited pathway toward commercialization to treat several unmet neurological m

MIRA : 1.1800 (-5.60%)
CARA : 5.13 (+1.38%)
CRBP : 6.79 (+5.76%)
HRMY : 32.72 (unch)
JAZZ : 137.96 (+1.40%)
Cara: Q3 Earnings Snapshot

Cara: Q3 Earnings Snapshot

CARA : 5.13 (+1.38%)
Cara: Q2 Earnings Snapshot

Cara: Q2 Earnings Snapshot

CARA : 5.13 (+1.38%)
Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

/CNW/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that England's National Institute for...

CARA : 5.13 (+1.38%)
Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

/PRNewswire/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that England's National Institute...

CARA : 5.13 (+1.38%)

Business Summary

Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States.

See More

Key Turning Points

3rd Resistance Point 5.30
2nd Resistance Point 5.22
1st Resistance Point 5.17
Last Price 5.13
1st Support Level 5.04
2nd Support Level 4.96
3rd Support Level 4.91

See More

52-Week High 11.52
Fibonacci 61.8% 8.15
Fibonacci 50% 7.11
Fibonacci 38.2% 6.07
Last Price 5.13
52-Week Low 2.71

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar